|
Neuralgia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
AURKB gene and protein expression was up-regulated concomitantly with the development of spinal microgliosis and neuropathic pain.
|
31563141 |
2020 |
|
MYELOPROLIFERATIVE SYNDROME, TRANSIENT
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results offer significant evidence towards the effectiveness of MDM2 inhibition in causing cell cycle arrest via blocking the transmission of signals through AURKB-CDK1 axis and inducing apoptosis in LNCaP-MST cancer cells.
|
31706019 |
2020 |
|
Infection by Cryptococcus neoformans
|
0.010 |
Biomarker
|
disease |
BEFREE |
Spatio-temporal regulation of nuclear division by Aurora B kinase Ipl1 in Cryptococcus neoformans.
|
30763303 |
2019 |
|
Dengue Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, these observations indicate that AurKB participates in DENV viral morphogenesis or release.
|
31626875 |
2019 |
|
Patent ductus arteriosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aim1 will estimate probability of spontaneous PDA closure and predict timing of ductal closure using echocardiographic, biomarker, and clinical predictors.
|
31519154 |
2019 |
|
Hip joint pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In Aim 1, the prevalence of hip pain was calculated using frequencies and crosstabs.
|
30736784 |
2019 |
|
Kaposi Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we reveal that N-cleaved isoforms of AURKB exist in several oncovirus-associated tumor cells and patient cancer tissues, including Kaposi's sarcoma-associated herpesvirus (KSHV), Epstein-Barr virus (EBV), and human papillomavirus virus (HPV).
|
30917319 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene set enrichment analysis (GSEA) identified the Aurora-A pathway, the Aurora-B pathway, and the FOXM1 transcription factor network as prognostic pathways in LUAD.
|
31198635 |
2019 |
|
Recurrent tumor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Therefore, these findings provide new evidence that barasertib regulates GC cell glucose metabolism by inducing the RPS7/C-Myc signal pathway, and have important implications for the development of therapeutic approaches using AURKB as a target protein to prevent tumor recurrence.
|
30540594 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of AURKB enhanced GC-induced expression of cell death genes, resulting in potentiation of GC cytotoxicity in cell lines and relapsed B-ALL patient samples.
|
30733284 |
2019 |
|
Chronic myeloproliferative disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings indicate that AURKA and AURKB participate in the JAK2/STAT signaling pathway and contribute to the MPN phenotype.
|
31289316 |
2019 |
|
Carcinoma of urinary bladder, invasive
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High baseline tumor AURKA and AURKB expression identified MIBC patients with inferior RFS and OS despite the use of NAC and may identify patients who should be prioritized for clinical trial enrollment rather than standard cisplatin-based chemotherapy.
|
31597600 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that dacomitinib diminished PDAC cell proliferation via inhibition of FOXM1 and its targets Aurora kinase B and cyclin B1.
|
31025257 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> 3-MA: 3-methyladenine; ATG5: autophagy related 5; ATG7: autophagy related 7; AURKA: aurora kinase A; AURKB: aurora kinase B; BECN1: beclin 1; CQ: chloroquine; DMSO: dimethyl sulfoxide; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; ERBB2: erb-b2 receptor tyrosine kinase 2; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; MTOR: mechanistic target of rapamycin kinase; PARP1: poly(ADP-ribose) polymerase 1; PI: propidium iodide; SQSTM1/p62: sequestosome 1; TNBC: triple-negative breast cancer.
|
30773992 |
2019 |
|
Hip pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In Aim 1, the prevalence of hip pain was calculated using frequencies and crosstabs.
|
30736784 |
2019 |
|
Myeloid Leukemia, Chronic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The most striking results were the LATS2 and AURKA overexpression in CML patients, the overexpression of TAZ and AURKB in CML patients at advanced phases and TAZ in CML IM-resistant.
|
29387948 |
2018 |
|
Obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To compare the prevalence of anxiety/depression and overweight/obesity (Aim 1) and the multimorbidity of these conditions (Aim 2) in a sample of adults with and without spinal cord injury (SCI).
|
30183556 |
2018 |
|
Pancreatic Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
A shift of the intracellular localization of aurora B might be useful for the subclassification of intermediate-grade intestinal NET and NEC (20%<Ki-67<55%), since detailed Ki-67-based guidelines only exist for the pancreatic tumors.
|
29970506 |
2018 |
|
Adenomatous Polyposis Coli
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The inhibition of PLK1 in mitotic, APC-∆C-expressing cells reduces the kinetochore levels of Aurora B and hampers the recruitment of SAC component suggesting a compromised mitotic checkpoint.
|
29549256 |
2018 |
|
Atresia
|
0.010 |
Biomarker
|
disease |
BEFREE |
SUMO2 modification of Aurora B and its impact on follicular development and atresia in the mouse ovary.
|
29512695 |
2018 |
|
Mixed anxiety and depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
To compare the prevalence of anxiety/depression and overweight/obesity (Aim 1) and the multimorbidity of these conditions (Aim 2) in a sample of adults with and without spinal cord injury (SCI).
|
30183556 |
2018 |
|
Asthenozoospermia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Down-regulated let-7b-5p represses glycolysis metabolism by targeting AURKB in asthenozoospermia.
|
29653228 |
2018 |
|
Behavioural and psychiatric symptoms of dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Primary Aim 1 is to determine if communities exposed to EIT-4-BPSD demonstrate evidence of implementation evaluated by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) criteria.
|
29485197 |
2018 |
|
Intestinal Neuroendocrine Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
A shift of the intracellular localization of aurora B might be useful for the subclassification of intermediate-grade intestinal NET and NEC (20%<Ki-67<55%), since detailed Ki-67-based guidelines only exist for the pancreatic tumors.
|
29970506 |
2018 |
|
Tumors of Adrenal Cortex
|
0.010 |
AlteredExpression
|
group |
BEFREE |
A previous study from our group suggested that elevated expression of aurora-A and aurora-B is associated with poor outcome in childhood ACT.
|
28410270 |
2017 |